Immune Responses to Human Immunodeficiency Virus (HIV) Type 1 Induced by Canarypox Expressing$HIV-1_mn$gpl20,$HIV-1_SF2$Recombinant gp120, or Both Vaccines in Seronegative Adults

A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10⁶ or 10⁷$TCID_50$of canarypox (ALVAC) vector expressing$HIV-I_{MN}$gp160 or$10^5.5$ $TCID_50$of ALVAC-rabies virus glycoprotein...

Full description

Saved in:
Bibliographic Details
Published in:The Journal of infectious diseases 1998-05, Vol.177 (5), p.1230-1246
Main Authors: Clements-Mann, Mary Lou, Weinhold, Kent, Matthews, Thomas J., Graham, Barney S., Gorse, Geoffrey J., Keefer, Michael C., McElrath, M. Juliana, Hsieh, Ray-Hahn, Mestecky, Jiri, Zolla-Pazner, Susan, Mascola, John, Schwartz, David, Siliciano, Robert, Corey, Lawrence, Wright, Peter F., Belshe, Robert, Dolin, Raphael, Jackson, Susan, Xu, Serena, Fast, Patricia, Walker, Mary Clare, Stablein, Don, Excler, Jean-Louis, Tartaglia, James, Duliege, Anne-Marie, Sinangil, Faruk, Paoletti, Enzo
Format: Article
Language:English
Subjects:
AIDS
Antibodies
Antigens
HIV
HIV 1
Immunization
Major Articles
Neutralizing antibodies
T lymphocytes
Vaccination
Vaccinia
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:A safety and immunogenicity trial was conducted in vaccinia-immune and vaccinia-naive human immunodeficiency virus (HIV)-uninfected adults who were randomized to receive 10⁶ or 10⁷$TCID_50$of canarypox (ALVAC) vector expressing$HIV-I_{MN}$gp160 or$10^5.5$ $TCID_50$of ALVAC-rabies virus glycoprotein control at 0 and 1 or 2 months and ALVAC-gp160 or 50 µg of$HIV-1_{SF2}$recombinant (r) gpl20 in microfluidized emulsion at 9 and 12 months; others received rgp120 at 0, 1, 6, and 12 months. All vaccines were well-tolerated. Neither vaccinia-immune status before vaccination nor ALVAC dose affected HIV immune responses.$HIV-I_{MN}$and$HIV-1_SF2$neutralizing antibodies were detected more often (100%) in ALVAC-gp160/rgp120 recipients than in recipients of ALVAC-gp160 (
ISSN:0022-1899